{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:51:27Z","timestamp":1782309087492,"version":"3.54.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.reumae.2026.502171","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:25:54Z","timestamp":1781522754000},"page":"502171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Causes of biologic therapy withdrawal in patients with rheumatic diseases: An observational cohort study from Southeastern Mexico"],"prefix":"10.1016","volume":"22","author":[{"given":"Angel Alejandro","family":"Castillo Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron Alejandro","family":"Barrera Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.reumae.2026.502171_bib0005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2026.502171_bib0010","article-title":"Survival of first line biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in Chile","volume":"21","author":"Olivar","year":"2025","journal-title":"Reumatol Clin"},{"issue":"7","key":"10.1016\/j.reumae.2026.502171_bib0015","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.reumae.2026.502171_bib0020","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.reumae.2026.502171_bib0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/RHU.0000000000002191","article-title":"Differences in clinical profiles and biologic treatment approaches for autoimmune rheumatic diseases across regions in Mexico","volume":"31","author":"Ter\u00e1n","year":"2025","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.reumae.2026.502171_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1559168","article-title":"High persistence of biologic therapy in patients with psoriatic arthritis: real-world evidence from a high-complexity hospital in Colombia","volume":"16","author":"Hormaza-Jaramillo","year":"2025","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.reumae.2026.502171_bib0035","article-title":"Cost-savings due to the withdrawing of biological therapy for treatment of rheumatoid arthritis in a specialized center in Colombia","volume":"20","author":"Santos-Moreno","year":"2017","journal-title":"Value Health"},{"issue":"4 Suppl 78","key":"10.1016\/j.reumae.2026.502171_bib0040","first-page":"S22","article-title":"Discontinuation of biologics in patients with rheumatoid arthritis","volume":"31","author":"Tanaka","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.reumae.2026.502171_bib0045","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s10067-016-3285-y","article-title":"Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis","volume":"35","author":"Galv\u00e3o","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.reumae.2026.502171_bib0050","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2023-eular.5232","article-title":"AB1358 Biologic treatment suspension and associated factors in patients with rheumatic diseases during the COVID-19 pandemic: data from BIOBADAMEX","volume":"82","author":"Ter\u00e1n","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2026.502171_bib0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/RHU.0000000000002269","article-title":"Clinical characteristics and 1-year response in rheumatic Mexican patients using JAK inhibitors: data from BIOBADAMEX","volume":"31","author":"Rivera-Ter\u00e1n","year":"2025","journal-title":"J Clin Rheumatol"},{"issue":"19","key":"10.1016\/j.reumae.2026.502171_bib0060","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s40265-014-0323-4","article-title":"Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis","volume":"74","author":"Tanaka","year":"2014","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.reumae.2026.502171_bib0065","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3899\/jrheum.121427","article-title":"Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis","volume":"40","author":"Aguilar-Lozano","year":"2013","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.reumae.2026.502171_bib0070","article-title":"POS0642 the impact of age on discontinuation of biologic DMARDs in patients with rheumatoid arthritis","volume":"80","author":"Teran","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"10.1016\/j.reumae.2026.502171_bib0075","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/annrheumdis-2017-eular.4348","article-title":"SAT0205 long-term drug survival and causes of discontinuation of subcutaneous abatacept in rheumatoid arthritis: 32-month results","volume":"76","author":"Sarmiento-Monroy","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"10.1016\/j.reumae.2026.502171_bib0080","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/annrheumdis-2016-eular.5732","article-title":"AB1081-HPR pharmacological adherence to conventional or biological therapy in patients with rheumatoid arthritis in a Colombian specialized rheumatology center","volume":"75","author":"Palacio","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"10.1016\/j.reumae.2026.502171_bib0085","first-page":"850","article-title":"Colombian Association of Rheumatology consensus on recommendations to decrease and discontinue biological therapy in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis","volume":"76","author":"J\u00e1uregui","year":"2017","journal-title":"Rev Colomb Reumatol (Engl Ed)"},{"issue":"10","key":"10.1016\/j.reumae.2026.502171_bib0090","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.23512","article-title":"Medical care costs associated with rheumatoid arthritis in the US: a systematic literature review and meta-analysis","volume":"70","author":"Hresko","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574326000845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574326000845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:39:26Z","timestamp":1782308366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574326000845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2173574326000845"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2026.502171","relation":{},"ISSN":["2173-5743"],"issn-type":[{"value":"2173-5743","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Causes of biologic therapy withdrawal in patients with rheumatic diseases: An observational cohort study from Southeastern Mexico","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2026.502171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2026.502171","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Reumatolog\u00eda (SER), Colegio Mexicano de Reumatolog\u00eda (CMR) and Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502171"}}